$BSL

BlueScope Steel Shares Making Decades High As Rally Continues

BlueScope Steel (ASX:BSL) rose 1.02% to A$33.79, near a 18-year high, after trading above the A$34.00 look-through value from the latest rejected non-binding takeover proposal. The board rejected an earlier A$30 offer and a revised A$32.35 offer. Investors also cite Feb earnings and a 2026 A$3.00/share capital return target.

Original reporting
Published Aug 4, 2026, 10:15 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 10:20 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
BlueScope Steel Shares Making Decades High As Rally Continues — source image
Decision brief

The 30-second read

$BSLBullishMed
01

Why it matters

Traders are likely to focus on whether the 17 August preliminary and annual report confirms second-half EBIT guidance and provides any update on takeover posture, since the stock is already trading near decade-high levels and close to the street consensus target.

02

Market read

The article frames a near-term decision point: whether fundamentals and cash returns can justify further gains after the stock breaks to decade highs, or whether takeover expectations drive the move.

03

What to watch

The article emphasizes non-binding takeover discussions; without a binding transaction, valuation support may rely heavily on execution of the 2026 capital return and EBIT guidance into the 17 August update.

Relevance 6/10Novelty 4/10Timing: ahead of 17 August preliminary and annual report

Background

BlueScope is in an ongoing, non-binding takeover process after SGH and Steel Dynamics submitted indicative offers that the board rejected as too low, while the company simultaneously delivered strong first-half results and outlined aggressive capital returns.

Company-level read

Ticker impact

$BSLBullishMedium confidence
Context

BlueScope shares hit a decades-high intraday level above the A$34.00 look-through value tied to the rejected SGH-Steel Dynamics offer.

Expected impact

Near-term upside may be capped unless the market gets confirmation of higher bid expectations or stronger-than-guided earnings at the 17 August report.

Evidence & confidence

The article provides concrete catalysts and reference levels: rejected A$32.35 bid, A$34.00 look-through, explicit 2026 capital return target, and upcoming 17 August preliminary/annual report that could update takeover posture and guidance.

Market effects

Strength in a major steel producer can support sentiment across industrials and steel-linked supply chains, especially where US spreads and construction demand are key drivers.

Could attract incremental ASX momentum flows into cyclicals if the takeover optionality narrative persists.

US steel spread sensitivity highlighted in the earnings drivers may keep global steel pricing and industrial demand in focus for traders.

Counterpoint

The stock trading above the consensus target and near the top of its range may reflect bid speculation rather than incremental fundamentals, increasing pullback risk if no higher offer emerges.

Key entities

  • BlueScope Steel

    ASX-listed steel producer whose shares are rallying on earnings strength, capital return targets, and takeover optionality.

  • SGH-Steel Dynamics consortium

    Bidders that submitted non-binding indicative and revised offers, with the board rejecting the initial proposal and discussing a higher look-through reference value.

Related articles

$BSLMed

BlueScope profit soars 800 per cent as it pivots to shareholder returns

BlueScope reported FY2026 net profit after tax of $802m, up 857% from FY2025, with EBIT of $1.27b. The company attributed the jump to an impairment charge rolling off and said it is shifting from heavy investment to shareholder returns. It declared an unfranked final dividend of 65c and special dividend of 70c per share. Safety and blast furnace upgrade timelines were also discussed.

$BSLMedAI 8/10

BlueScope FY profit jumps over 100% on U.S., Asia strength

BlueScope reported annual underlying net profit after tax of A$851.2 million, up from A$420.8 million, citing stronger U.S. steel spreads and improved Southeast Asian operations. It forecast underlying EBIT for 1H 2027 of A$860 million to A$960 million. BlueScope declared a final dividend of 65 cents and a special dividend of 70 cents per share, and plans to return A$3 per share in FY2027.

$INFYMed

TCS, Infosys shares on hold? Time to buy midcap IT stocks, says Antique

Antique Stock Broking kept “Hold” ratings on largecap IT services—TCS (target Rs 2,900), Infosys (Rs 1,390), HCL Tech (Rs 1,430), Wipro (Rs 225), Tech Mahindra (Rs 1,550)—and preferred select midcaps Coforge (Rs 5,625) and Mphasis (Rs 1,875) as well as other “Buy” names. It cited cautious US retail commentary, fading tax-refund benefits, and macro risks. It expects gradual erosion of traditional services and says AI monetization is the key theme.

$ROIVMedAI 8/10

What Lisraya’s $35,000 Monthly Price Could Mean for Roivant (ROIV)

Roivant Sciences (ROIV) and Priovant Therapeutics launched Lisraya, a $35,000/month dermatomyositis treatment, post-FDA approval. The drug's high price and small patient population present challenges, but its immediate launch and long exclusivity may drive adoption. ROIV owns 71% of Priovant, making Lisraya's success crucial for its financial outlook.